Alluvi, formerly BI 4744, presents a promising breakthrough in obesity therapy. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates compelling results in https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/